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Patients with systemic mastocytosis (SM) have a wide variety of problems, including skeletal abnormalities. The disease results
from a mutation of the stem cell receptor (c-kit) in mast cells and we wondered if the function of bone marrow stromal cells
(BMSCs; also known as MSCs or mesenchymal stem cells) might be affected by the invasion of bone marrow by mutant mast
cells. As expected, BMSCs from SM patients do not have a mutation in c-kit, but they proliferate poorly. In addition, while
osteogenic differentiation of the BMSCs seems to be deficient, their adipogenic potential appears to be increased. Since the
hematopoietic supportive abilities of BMSCs are also important, we also studied the engraftment in NSG mice of human CD34+
hematopoietic progenitors, after being co-cultured with BMSCs of healthy volunteers vs. BMSCs derived from patients with SM.
BMSCs derived from the bone marrow of patients with SM could not support hematopoiesis to the extent that healthy BMSCs do.
Finally, we performed an expression analysis and found significant differences between healthy and SM derived BMSCs in the
expression of genes with a variety of functions, including the WNT signaling, ossification, and bone remodeling. We suggest that
some of the symptoms associated with SM might be driven by epigenetic changes in BMSCs caused by dysfunctional mast cells in
the bone marrow of the patients.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).⁎ Corresponding authors.
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Mast cells express c-kit (CD117), which is the stem cell factor
(SCF) receptor. When this receptor is constitutively activat-
ed due to genetic mutation(s), an increase in mast cell (MC)
proliferation occurs and leads to the disease systemicn access article under the CC BY-NC-ND license
43Impaired function of bone marrow stromal cells in systemic mastocytosismastocytosis (SM) (Carter et al., 2014). More than 90% of
patients with SM carry the somatic D816V activating
mutation in the KIT gene (Nagata et al., 1997). The over
proliferation of MCs in the bone marrow (BM) results in an
alteration in the expression of additional genes (D'Ambrosio
et al., 2003) and mediators including histamine within the
bone marrow and thus a change in the immediate environ-
ment of bone marrow stromal cells (BMSCs, also known as
bone marrow-derived mesenchymal stem cells or MSCs) that
are responsible for generating cartilage, bone and marrow
adipocytes in BM during bone turnover and repair, as well as
supporting hematopoiesis.
A number of pathologic features of SM suggest a possible
link between specific disease findings and a role for BMSCs.
These include the well-documented skeletal disease in
patients with SM (Delsignore et al., 1996; Rossini et al.,
2014), and abnormalities in the cellular composition of the
BM including anemia (George and Horny, 2011). As we have
previously established that the human BMSCs bear all four
histamine receptors (Nemeth et al., 2012), we wanted to
examine if the increase in MCs might be associated with
abnormalities of the BMSC compartment which might in turn
impact disease pathology.Methods
Patients
Patients with SM were evaluated at the National Institutes of
Health (NIH; Bethesda, MD) as part of Institutional Review
Board (IRB)-approved research protocol designed to study the
pathogenesis of SM (NCT00044122) and were diagnosed
according to the World Health Organization (WHO) criteria.
KIT D816V mutation analysis was performed described (Maric
et al., 2007). Healthy controls participated under the IRB
approved protocol NCT01071577. The biopsy and aspirates
were obtained from the same affected site of the patients.
Neoplastic mast cell “free” aspirates were not obtained.
Although of scientific interest, obtaining these samples would
have been technically challenging and would have subjected
the patients to repeated bone marrow aspirations.Culturing of BMSCs
Bone marrow aspirates were diluted according to cell counts
and we plated 0.25–0.5 × 106 nucleated cells/cm2 in 75-cm2
culture flasks (patient samples did not always have this
number of cells available) and incubated the cells in complete
medium for 24 h in a 37 °C, 5% CO2 incubator. The medium
was changed every 3 days and cells were passaged before
reaching confluency. To isolate normal and abnormal
colonies the patients' BMSCs were grown in a flask and
monitored daily. When the colonies were large enough to
determine their nature, the top of the flask was removed
and the normal and abnormal looking colonies were
isolated and seeded again in separate culture plates.
Since the abnormal colonies grew very slowly and stopped
growing very early, we had to pool the abnormal colonies to
have enough cells for experiments to perform. For more
details see Nemeth et al. (2013).Proliferation studies of BMSCs
BMSCs were serum starved in a basal medium for 72 h. 5000
human serum starved BMSCs were plated in 96-well plates/
200 μL each well. After an overnight incubation the serum
free medium was changed to either 20% serum medium or
basal medium containing 10 ng/mL FGF-2. Twenty-four
hours later BrdU was added at a final cc of 10 μM. After
another 12 h cells were fixed with fix-perm buffer and the
next steps were done according to the Roche BrdU ELISA
protocol.Beta-galactosidase (β-gal) staining of expanded
BMSC
BMSCs were stained using a senescence associated beta-gal
staining kit (Sigma Aldrich, St. Louis, MO) following the
manufacturer's protocol. Briefly, BMSCs were washed with
PBS, fixed with a fixation buffer for 7 min at room
temperature, washed with PBS, and then incubated with a
staining mixture at 37 °C overnight. The senescent cells
under 10 randomly selected high-magnitude microscope
fields (100×) were counted on the following day.Primary colony-forming efficiency (CFE) and
measurement of CD34+ cells of bonemarrow aspirate
Primary CFE of bone marrow aspirates was analyzed by
methods as reported previously (Sabatino et al., 2012).
Briefly, 1 × 105 nucleated cells were plated in a T25 flask
(Corning, Corning, NY) in duplicate and cultured for 13 days
without changing the culture medium. The colonies were
fixed with methanol for 30 min and stained with saturated
methyl-violet water solution for 20 min. Colonies were
observed under a low magnitude light microscope field
(25×). Colonies containing 50 or more cells of fibroblastic
morphology were counted (Sabatino et al., 2012).
The percentage of CD34+ hematopoietic progenitor cell
(HPC) was determined by following standardized protocols in
the Cell Processing Section (CPS), Department of Transfusion
Medicine, Clinical Center of NIH. Briefly, 1 × 106 nucleated
cells were incubated with CD34 APC, CD3 PE-Cy7, 7AAD and
CD45 APC-Cy7 (BD Biosciences, San Jose, CA) for 20 min at
4° and then lysed in a lysis washing assistant equipment (BD
Biosciences). The CD34+ percentage was measured on a
FACSCanto cytometer (BD Biosciences) (Sabatino et al.,
2012; Ren et al., 2013).Population doubling (PD) curve of expanded BMSC
PD was calculated to analyze the proliferation of BMSC.
The number of BMSCs at each passage was manually counted
and the PD for each passage was calculated using equation:
N = log2 (NH/N1) where N = population doublings, N H = cell
harvest number, N I = plating cell number, and the cumula-
tive PDs were calculated in relation to the number of cells
at the first passage (Sabatino et al., 2012; Ren et al., 2013).
44 K. Nemeth et al.FACS analysis of BMSCs
Cells were incubated with corresponding antibodies for
15 min on 4° in a FACS buffer (1× PBS/1%BSA). FACS was
performed using FACSCalibur. Data were analyzed with
FlowJo. The antibodies used were as follows: anti-CD44 PE
BD Biosciences (Cat No 555479), anti-CD45 FITC BD Biosci-
ences (Cat No 555482), anti-CD90-PE eBioscience (Cat No
12-0909), anti-CD105-PE eBioscience (Cat No 12-1057),
anti-CD146-FITC Abcam (Cat No ab78451), and anti-CD166-
PE BD Biosciences (Cat No 560903).
Osteogenic and adipogenic differentiation assay of
BMSCs
In vitro bone and adipose stimulation assays were performed
as reported earlier (Nemeth et al., 2013). 0.3 million pooled
MSCs were plated in 6 well plates in complete MSC medium.
After 72 h the medium was changed to either osteogenic or
adipogenic medium. After 14 days cells were fixed and
stained with Alizarin Red or Oil Red respectively. Represen-
tative wells are shown.
Histamine stimulation of BMSCs followed by adipogenic
differentiation assay
25 k BMSCs were plated in 12 well plates in complete MSC
medium. Histamine dihydrochloride (Abcam) was added
once every day for a week to maintain a 10−7 M concentra-
tion in the wells of the experimental samples, while control
BMSCs received vehicle only. After one week the adipogenic
differentiation assay was started in all wells. After 14 days,
total RNA was isolated using the Quick-RNA Mini Prep kit
(Zymo Research) according to the manufacturer's instruc-
tions. Isolated total RNA was reverse transcribed using
oligo-dT primers and the Moloney-murine leukemia virus
reverse transcriptase according to the instructions of the
manufacturer (Promega, Madison, WI).
The resultant cDNA was amplified with QuantiTect SYBR
Green RT-PCR kit (Qiagen) using primers ACGAAGA
CATTCCATTCACAA (sense) and CTCCACAGACACGAC ATTC
(antisense) corresponding to 166–186 and 345–363 of
GenBank sequence XM_006713208.1. RT-PCR conditions
were as follows: 95 °C for 15 min initial activation of the
Taq polymerase and denaturation of the reverse transcrip-
tase and then 45 cycles of 94 °C for 15 s denaturation,
primer-specific temperatures for 30 s annealing (PPARG2
55 °C, ACTB 60 °C), and 72 °C for 30 s extension.
Human CD34+ cell engraftment experiment after
BMSC co-culture
Pooled samples of human BMSCs (from healthy donors or
mastocytosis patients) were seeded in 6 well plates
(0.25 million cells/3 mL in each well) in complete MEM-
alpha medium and were grown to confluence. Mitomycin
pretreatment was performed by incubating BMSCs in
complete MSC medium containing 10 μg/mL final concen-
tration of mitomycin C for 2 h. This was followed by vigorous
washes 5 times with PBS.Peripheral blood CD34+ cells (PB CD34+) were obtained
from healthy adult volunteers. Briefly, volunteers received
5 days of 10 μg/kg recombinant human (rHu) granulocyte
colony-stimulating factor (G-CSF, Amgen, Thousand Oaks,
CA). On day 5 of mobilization, PB CD34+ cells were collected
by one 12–15-L leukopheresis, and CD34-positive selection
was performed using the Isolex 300i automated immuno-
magnetic system (Nexell, Miltenyi, Auburn, CA). CD34+ cells
(2 million/well) were added to each well in StemSpan
medium containing 25 ng/mL of SCF, Tpo, and Flt3-ligand.
8–10 week old male NOD-SCID-Gamma (NSG) mice from
JAX (King et al., 2009) were used as recipients (5 mice were
used in each group). Busulfan (Busulfex, Otsuka Pharmaceu-
tical, Rockville, MD) was diluted with PBS to deliver 35 mg/kg
in a final volume of 400 μL and was injected into recipient
mice intraperitoneally 24 h prior to the cell infusion. Cultured
cells were filtered through a 40 μm strainer and subsequently
injected in a total volume of 200 μL PBS. After 5 days of
co-culture the CD34+ cells were collected, counted, and
injected intravenously via the tail vein into the busulfan
pretreated mice at a concentration of 1 million cells/300 μL
PBS.
Four weeks after transplantation blood was collected
from the recipient animals to check for human cell
chimerism. After RBC lysis, using ACK lysing buffer, FACS
was performed using mouse and human CD45 specific
antibodies. The percentage of human CD45+ cells was
determined as a marker of engraftment.
Gene expression profiling on BMSCs from healthy
donors and MS patients
The gene expression profiling was performed by following
standard protocols in CPS (Ren et al., 2013). Briefly, the
BMSCs from 3 age-matched SM patients (30.3 ± 8.5 years)
and healthy donors (34.7 ± 6.8 years) were selected for
analysis. Total RNA was extracted and labeled with Cy5-CTP
and human reference RNA (was labeled with Cy3-CTP). The
labeled cRNA was pooled, fragmented and then hybridized
on 4 × 44 K microarrays (Agilent, Santa Clara, CA) for 17 h at
65 °C. The microarrays were then washed and scanned using
an Agilent Scanner and data were acquired using Agilent
Feature Extraction Software. The raw data was uploaded
into mAdb database (http://madb.nci.nih.gov/) and then
analyzed by BRB-ArrayTools (Simon et al., 2007) (http://
linus.nci.nih.gov/BRB-ArrayTools.html) and Partek Geno-
mics Suite (Partek Inc., Saint Louis, MO). Tests for
differences between MS patients and healthy donors were
conducted for individual genes using a t-test, considering
p-values of b0.001 as significant. The functional relevance
of the differentially expressed genes was annotated by using
MetaCore database (https://portal.genego.com/) following
its instructions.
Mutational analysis of SM patients' derived cultured
BMSCs
DNA extraction
One million stromal cells cultured from mastocytosis
patients were lysed and genomic DNA (gDNA) was prepared
by using a QIAamp DNA blood mini kit (QIAgen) and eluted in
45Impaired function of bone marrow stromal cells in systemic mastocytosis100 μL of elution buffer. Genomic DNA from HMC1.2 cells
(KIT D816V heterozygous) (Sundstrom et al., 2003) were also
prepared as was stromal cell genomic DNA and used as the
KIT D816V mutation positive control. Genomic DNA from
PBMCs of healthy volunteers was prepared and used as a
negative control.
Allele specific qPCR for KIT D816V mutation
Two real-time qPCR assays were performed using the
TaqMan Universal PCR Master Mix with AmpErase UNG onFigure 1 BMSC morphology and proliferation differs between hea
B. (high magnification) show a 7 day culture of BMSCs from normal
magnification) that are samples of SM patients. All images were p
F. Patient sample demonstrate β-gal staining, a marker of senescenc
proliferation was assessed by BrdU incorporation, also suggesting t
disadvantaged. The samples were pooled from 3 patients and thr
experiments were performed in triplicate samples. Abbreviations: FG
(E, F). Statistical significance is labeled as ** = p b 0.01 and *** = pthe 7500 Real Time PCR System (Applied Biosystems, Foster
City, CA). The KIT D816V mutation specific assay amplifies
KIT D816V alleles, and the control assay amplifies both
wild-type KIT and D816V KIT alleles. The forward and reverse
primer, TaqMan probe sequences and conditions for the
qPCR assays were used as described (Kristensen et al.,
2011). A 4-fold dilution series of HMC1.2 cell gDNA was used
as standards to perform qPCR assays on same plate for
absolute quantification and for calculating PCR efficiencies
of mutation-specific and control assays. Real-time qPCR waslthy controls and patients with SM. A. (Low magnification) and
volunteers compared with C. (low magnification) and D. (high
hotographed under the same conditions. E. Normal donor and
e, strongly labeling cells in the patient's culture. G. The rate of
hat in all conditions, the BMSCs from the patients seem to be
ee volunteers to get enough cells to perform the assays. The
F2 = fibroblast growth factor 2; Scale: 100 μm (A–D) and 50 μm
b 0.001.
46 K. Nemeth et al.performed with 50 ng sample gDNA in a total 25 μL reaction
volume. All samples were performed in triplicate. Data was
analyzed using SDS software version 1.3.1 (Applied
Biosystems). Percent KIT D816V allele was calculated based
on the formula described (Kristensen et al., 2011). The
mutation positive was determined as 2 of 3 or 3 of 3
reactions generating a threshold cycle (Ct) value below 41.
The mutation negative was defined as none of three
reactions producing a Ct value below 44.
Results
BMSCs from patients with SM show abnormal
morphology and growth characteristics
BMSCs from healthy volunteers (Figs. 1A, B) and patients
with SM (Figs. 1C, D) were plated as published earlier
(Nemeth et al., 2012, 2013) and the cultures were examinedPrimary CFE of Bone Marrow Aspirate/10  cells5
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controls.1 week later. BMSCs from the patients were growing very
slowly, thus they were difficult to culture and exhibited
signs of senescence (large, flat morphology) in early
cultures. These cells showed β-gal staining indicating
senescence, while normally growing cells did not (Figs. 1E,
F). We tested the proliferative ability of the patient's BMSCs
by using BrdU and adding serum or FGF2 to the medium. In
all conditions the proliferation of the patients' BMSCs was
significantly (p b 0.01 to p b 0.001) less than those from
healthy donors (Fig. 1G).
Next we compared primary colony forming efficiency
(CFE) of BMSCs from healthy and diseased BM. We found that
from primary bone marrow aspirates, the CFE from the
patients with SM was significantly below (p b 0.01) that of
the healthy volunteers (1.5 ± 1.8 vs. 10.1 ± 1.7 in 100,000
plated cells respectively) (Fig. 2A). While the CFE was very
different between the donor and the patient groups, we
found that the percentage of CD34+ hematopoietic progen-
itors were similar (Fig. 2B). We then compared the numberCD34 % of Bone Marrow aspirate
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47Impaired function of bone marrow stromal cells in systemic mastocytosisof population doublings over time between healthy BMSCs
(n = 7) vs. BMSCs from patients with SM (n = 10). As can be
seen, BMSCs from patients with SM exhibited fewer dou-
blings over time compared with BMSCs from the healthy
counterparts (Figs. 2C, D). Since the patient group was older
on average than the normal volunteer group, we used the
available age matched samples (all 40 ± 2 years) and
noticed a similar difference (Fig. 2E).BMSCs from the BM of patients with SMC do not carry
the KIT D816V mutation
SM is associated with somatic mutations in KIT that occur in
hematopoietic stem cells and affect the mast cell lineage.
We next determined if in addition to MCs, the BMSCs might
also harbor the KIT D816V mutation. BMSCs were cultured
from 5 patients and submitted to KIT D816V analysis by
real-time qPCR. The KIT D816V mutation was not detected in
the cultured BMSCs of patients with SM.BMSCs from patients appear as a mixture of normal
and abnormal cells
When we plated the BMSCs from the patients, we noticed
that some areas on the plate that appeared to show normal
growth were exhibiting the typical “swirly” pattern and
easily growing. On the other hand there were some very
sparsely populated areas, where the cells looked large, flat
and showed no pattern of swirling (reminiscent of senescent
cells) that were growing slowly or not at all and were
positive for β-gal staining (Figs. 3A, B). The normal vs.
abnormal colonies were counted from 10 patient samples
and their respective numbers were: 3 vs. 16, 13 vs. 5, 5 vs. 6,
3 vs. 11, 0 vs. 3,1 vs. 8, 0 vs. 5,4 vs. 4, 0 vs. 11, and 2 vs. 8,
respectively. The average of these data were 3.1 (healthy)
vs. 7.7 (abnormal) that reached statistical significance
(p b 0.017). To further explore this observation, and after
plating aspirates at a clonal density, we next isolated and
cultured cells from both normal (N = 5–20/patient) and
abnormal appearing colonies (N = 2–8/patient) from the
patients' primary BM aspirate. We first cultured the cells in aFigure 3 Normal and abnormal colonies of BMSCs appear within
morphology (A) are shown next to scattered, abnormally looking se
colonies from the same culture dish.flask, and once the colonies began to proliferate we picked
cells from both types of colonies for study (Suppl. Fig. 1). We
then separately pooled cells from both types of colonies to
obtain enough cells for assay, as dictated by the slow growth
of abnormal-appearing colonies. We then examined the cells
for the presence of known BMSC surface markers. We found
that the mean fluorescent intensity of CD 105 (endoglin)
seems to be slightly higher in cells from the pooled normal
colonies and greatly overexpressed in cells from the
abnormal colonies of mastocytosis patients (Fig. 4A; red)
compared with BMSCs from normal donors (blue). In
addition, the mean fluorescent intensity of CD146 appeared
to be decreased in cells from the abnormal colonies
compared with cells from normal clones and BMSCs from
normal donors (Fig. 4A).Functional differences between cells from abnormal
MC colonies in osteogeneic and adipogeneic
differentiation compared with normal MC colonies
We next examined whether the morphologic and surface
molecule differences are associated with functional differ-
ences between the normal and abnormal MC colonies. Using
pooled abnormal and normal colonies we performed osteo-
genesis and adipogenesis assays (Nemeth et al., 2013). The
pooled abnormal colonies were found to produce less
calcified matrix than the normal colonies. At the same
time they appeared to produce more adipose tissue than
their normal counterparts (Fig. 4B).
Since human BMSCs bear all four histamine receptors (6),
we wanted to examine the effect of histamine produced
by mast cells on the BMSC cultures. When human BMSCs were
cultured for two weeks in histamine rich media, the
mRNA encoding peroxisome proliferator-activated receptor
gamma (PPARγ) was significantly unregulated at a concen-
tration of 10−7 M histamine in the medium (data not shown).
This is a nuclear receptor protein that acts as transcription
factor to regulate genes and its expression indicates the
ability of the cells to differentiate towards adipogenic vs.
osteogenic direction. In two experiments there were 1.6
and 2.5-fold increases (p b 0.002), respective-lee, of PPARγthe same patient sample. BMSCs that show normal growth and
nescent cells (B). Both cell populations were grown from single
CONTROL
   BMSC
ABNORMAL
   MASTO
NORMAL
 MASTO
**
% OF ENGRAFTED HUMAN CD45  CELLS
+
B
C
D
Inject iv into busulphan treated NSG mice
(NOD/SCID/IL2R gamma chain triple KO)
CD34  cells from healthy donors
Added BMSC  
(Control and normal or abnormal
      from mastocytosis patients)
Culture for 5 Days
+
 4 weeks later FACS to
analyse for % of HuCD45
    cells in blood
+
Study hematopoietic support by different BMSC colonies
Osteo-differentiation
Normal colony
Normal colony
Osteo-differentiation
Adipo-differentiation Adipo-differentiation
Abnormal colony
Abnormal colony
A
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
CD44 Abnormal M CD44 Normal M
CD90 Abnormal M CD90 Normal M
CD105 Abnormal M CD105 Normal M
CD166 Abnormal M
CD146 Abnormal M CD146 Normal M
CD166 Normal M
*
5                             100
Figure 4 Differences between normal and abnormal colonies taken from the same patient's sample. A. Five accepted markers of
BMSCs were used in FACS analysis to compare the abnormal (left column) and normal (right column) cells (red) from patients with SM
to healthy donor BMSCs (blue). Green denotes the unstained control. The mean fluorescent intensity of CD105 appeared higher in the
patients' samples, while they are lower for CD146. For details of antibodies used see Methods section. B. Using osteogenic and
adipogenic tissue culture media we demonstrated that the abnormal colonies are not able to form a calcified matrix (as shown by
Alizarin red staining that labels calcium), but seem to produce more fat cells (as shown by Oil red staining). C. Illustration of the
technique of studying engraftment of human CD34+ hematopoietic progenitors in immune-compromised NSG mice. Following
co-culturing the CD34+ cells with BMSCs derived from healthy donors, or normal and abnormal colonies from patients, the CD34+ cells
are injected into NSG mice previously treated with busulfan; and 4 weeks later, engraftment is determined by the percentage of
human CD45+ cells in the peripheral blood. D. shows that BMSCs from healthy donors better support CD34+ progenitors to form more
blood cells than those derived from normal and abnormal cells from patients. Five mice were used in each group. Statistical
significance is labeled as * = p b 0.05 and ** = p b 0.05.
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49Impaired function of bone marrow stromal cells in systemic mastocytosismRNA isolated from hBMSCs cultured with 10−7 M histamine
vs. control BMSCs.
Abnormal MC BMSCs are deficient in supporting
hematopoiesis
Since an important and unique role of BMSCs is hematopoi-
etic support, we next performed an experiment to see if
there is any change in this function. We co-cultured healthy
human CD34+ progenitors with BMSCs derived from normal
donors, and BMSCs grown from both normal and abnormal
colonies from patients with SM. Following a 4-day co-
culture, we transplanted these hematopoietic progenitors
into immune-compromised (NSG–NOD/SCID/IL2 receptor
gamma chain triple KO), busulfan treated mice. Four weeks
later we analyzed the peripheral blood to determine the
percentage of human CD45+ cells (Fig. 4C). We found that
the mice transplanted with cells previously co-cultured with
the pooled abnormal SM BMSC colonies had significantly
(p b 0.01) less huCD45+ cells in circulation than the mice
transplanted with cells cultured with BMSCs from healthy
donors (9 + 1.4 vs. 3.7 + 1.1%). There was also a significant
(p b 0.05) difference in the effects on support of human
blood cells between the normal and abnormal pooled clones
from patients with SM; the pooled normal colonies producing
lower values than healthy donors, but higher values than the
abnormal clones (Fig. 4D).
Gene expression profiling on BMSCs from healthy
donors and MS patients
Gene expression profiling was performed on BMSCs from
patients with SM (n = 3) compared to those from normal
donors (n = 3). Among all of the genes evaluated, 6885 wereMastocytosis
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Figure 5 Gene expression profiling on BMSCs from mastocytosi
performed on BMSCs from 3 age-matched MS patients and donors. A.
least 1 sample were used to run the Principal Component Analysis (P
were separated from those from normal donors (red spheres). B. The
and 410 genes were up-regulated in BMSCs from MC patients (red d
dots, fold change N =2), x-axis indicates the log2 fold change of madetected to change compared to normal donors by more
than 1.5-fold in at least 1 sample; and Principal Component
Analysis (PCA) using these genes separated the samples into
2 clusters, one with BMSCs from donors and the other BMSCs
from patients with SM (Fig. 5A), clearly indicating a disparity
between these cell groups. We then identified genes that
were differentially expressed between patients with SM and
normal donors by using t-test (p-value b 0.001). Among
these genes, 410 were up-regulated in BMSCs from patients
by more than 2-fold (red), while 185 were down-regulated
(green) (Fig. 5B). The functions of these genes were
annotated with the MetaCore database, and 16 significantly
changed networks with a p-value of less than 0.05 were
identified (Table 1). When comparing gene array data with
BMSCs from normal volunteers, we found down-regulation in
the SM BMSCs of certain bone and cartilage and up-regula-
tion of adipose tissue differentiation related genes. BMP4
(2.3-fold p b 0.009); Runx2 (2-fold p b 0.001); ALPL (2-fold
p b 0.045) and BGN (1.25-fold p b 0.19) involved in osteo-
genic differentiation and COL12A1 (1.69-fold p b 0.045) and
COL10A1 (6.1-fold p b 0.001) involved in cartilaginous
differentiation were all down-regulated in the SM patients'
samples. PPARG (0.5-fold p b 0.027) and CEBPA (0.4-fold
p b 0.001) on the other hand were up-regulated in SM
BMSCs, and are indicators of adipogenic differentiation
ability.
We also looked for differences between BMSCs from
normal volunteers vs. patients in expression of genes
encoding factors that might affect the hematopoietic
support function of the cells. The results showed a
significant down-regulation in SM derived BMSCs of CXCL12
(0.5-fold p b 0.0003), PDGFα (0.66-fold p b 0.004), VCAM1
(0.36-fold p b 0.0004) and FGF7 (0.27-fold p b 0.00001),
which are known to be important in the hematopoietic
support function of BMSCs.Log2 FC (MC/Donor)
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s patients and healthy donors. Gene expression profiling was
The genes that were detected by more than 1.5-fold change in at
CA) (Ren et al., 2013). The BMSCs from patients (blue spheres)
differentially expressed genes were identified by using a t-test,
ots, fold change N =2), while 185 were down-regulated (green
stocytosis/donor, y-axis indicates the − log10 (p-value).
Table 1 MetaCore networks of significant genes.
MetaCore networks p-Value Genes
Blood coagulation 7.03E−05 SERPINA6 (1.51), ADAMTS14 (−1.31), LMAN1 (− .24), MST1 (1.03), KRT18 (1.25),
VWF (1), KNG1 (1.74), F11 (1.69), TMPRSS6 (1.09)
WNT signaling 2.63E−03 ESR1 (1.40), TGFB3 (−1.22), WNT10B (1.47), WNT6 (1.74), FOXA2 (1.84),
APC (−1.01), ADCY1 (1.29), NFATC1 (−1), SFRP1 (2.47)
IL-2 signaling 8.45E−03 ESR1 (1.40), SYK (1.60), NFATC1 (−1), LCK (1.64), CCR2 (1.32), BCL2 (−1.02),
TMPRSS6 (1.09)
Blood vessel morphogenesis 1.03E−02 PDE6B (1.56), NPR1 (1.47), TBX1 (1.43), TNNC1 (1.12), MMP19 (−1.15), VCAM1
(−1.46), CEACAM6 (1.25), GRB7 (1.56), FOXF1 (2.40)
Ossification and bone
remodeling
1.73E−02 IGFBP4 (1.12), TGFB3 (−1.22), CHRDL1 (−1.10), WNT6 (1.74), WNT10B (1.47),
COL10A1 (−2.60), TWIST1 (−1.06), RUNX2 (−1.03)
Connective tissue degradation 1.93E−02 LNPEP (−1.18), ADAMTS14 (−1.31), PCSK6 (2.56), CTSG (1.60), MMP19 (−1.15),
TMPRSS6 (1.09)
Kallikrein–kinin system 2.29E−02 ADAMTS14 (−1.31), KNG1 (1.74), VWF (1.0), NOS2 (1.0), KNG1 (1.74), PTGES2
(1.09), F11 (1.69)
ECM remodeling 2.46E−02 ADAMTS14 (−1.31), PCSK6 (2.56), CSTG (1.60), MMP19 (−1.15), COL10A1 (−2.60)
Hedgehog signaling 2.53E−02 GAS1 (−1.30), TBX1 (1.43), FOXA2 (1.84), ADCY1 (1.29), JAG2 (1.60), BMI1 (−1.57),
GLI1 (−1.49), FOXF1 (2.40), EYA2 (−1.16), CDC37 (1.40), SOX8 (2.0), SOX3 (3.18)
Feeding and neurohormone
signaling
2.66E−02 TAC3 (1.25), KIT (1.64), TGFB3 (−1.22), ADCY1 (1.29), CCR2 (1.32), GLI1 (−1.49),
BCL2 (−1.04)
Bile acids transport and its
regulation
2.70E−02 SULT2A1 (2.25), ABCC4 (−1.02), ABCG5 (2.12), ABCB1 (1.51)
Muscle contraction 3.26E−02 THBS1 (−1.15), GUCA1B (1.25), KCNH2 (1.64), NPR1 (1.47), TNNC1 (1.12), GAL
(1.64), MYBPH (−1.41), GUCA1B (1.25)
Regulation of angiogenesis 3.92E−02 EFNA1 (1.0), IL1R1 (−1.18), THBS1 (−1.15), GLI1 (−1.49), CARD11 (1.47)
Neurogenesis 4.17E−02 CACNA1B (1.06), RIMS4 (1.36), PCP4 (1.09), SYT3 (1.32), THBS1 (−1.15), WNT6
(1.74), WNT10B (1.47), POU4F1 (1.32), ERBB3 (1.03)
Visual perception 4.45E−02 PDE6B (1.56), GUCA1B (1.25), MYO7A (1.12), PRPH (1.15), RLBP1 (2.25)
Leucocyte chemotaxis 4.53E−02 LPAR2 (1.15), LIMK1 (−1.10), SKAP1 (2.40), VCAM1 (−1.47), CD2 (2.06), LCK
(1.64), CCL17 (1.22), CCR2 (1.32)
The names of genes were shown; the values indicate the log2 (fold change) of mastocytosis/donor.
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Mastocytosis is a rare disease characterized by an abnormal
accumulation of mast cells in a number of tissues including the
marrow, liver, spleen, lymph nodes and skin. In SM, the bone
marrow is consistently affected (George and Horny, 2011) and
skeletal abnormalities are well described (Delsignore et al.,
1996; Abramowitz and Weinerman, 2012; Hermine et al., 2008;
Lim et al., 2009). Since the bone marrow is home to not only
the hematopoietic stem and progenitor cells, but also the
BMSCs that maintain the BM environment, we were interested
in whether the disease affects these cells as well and be
associated with abnormal function.
In the work presented, we found that BMSCs from patients
with SM have a slower growth rate and a shorter life span than
those from healthy donors. Since SM is associated with
somatic activating mutations in KIT (Carter et al., 2014;
Horny et al., 2007; Longley et al., 1999; Pardanani, 2012), we
first wanted to determine if the BMSCs also carry the KIT
D816V mutation. All 5 patients' BMSCs examined for the
mutation showed no presence of a mutant KIT D816V allele.
This result suggests that the slow growth rate and early
senescence of the BMSCs from patients with SM is most likely
due to epigenetic factors. These effects might be due to a
variety of factors. For example, MCs release histamine and
BMSCs bear histamine receptors. A chronically increased
histamine concentration in the tissue environment mightproduce epigenetic changes — such as disturbances in growth
properties as well as affecting their “stamens”. It is possible
that as the disease progresses, increasingly more BMSC clones
become abnormal, thus compounding the disease state for
these patients (for detailed patients' data see Table 2).
Histamine also induces the BMSC production of IL-6 and IL-8
(Nemeth et al., 2012) and high levels of these cytokines might
also affect the composition of the environment surrounding
the BMSCs. In addition to histamine, mast cell secretory
granules contain other mediators (proteases, proteoglycans,
heparin, heparan sulfates, cytokines etc.) that are released
into the environment upon cell stimulation. All of these MC
derived factors might have an effect on the biology of the
BMSCs in the bone marrow niche and the effect of all these
factors individually and in combination will also need to be
examined in the future.
Our in vitro data exposing healthy BMSCs to high levels of
histamine revealed an elevation of a peroxisome proliferator-
activated receptor (PPAR) gamma mRNA in the cells. PPARγ
is a prime inducer of adipogenesis in BMSCs and its
elevation shifts the differentiation potential of BMSCs
from osteogenic towards adipogenic lineage (Takada et
al., 2009). Due to the exposure of high levels of histamine
over a long period of time in the BM of SM patients, this
shift could partially explain the poor osteogenic differen-
tiation of the cells and could underlie some of the skeletal
problems of these patients.
Table 2 Patients' data and summary of usage of BMSCs.
Used for Date BSI ID DIN Age Gender Classification Tryptase
(ng/mL)
Mast celll
aggregates
% involvement N25%
spindle
shaped
CD2 CD25 KIT
mutation
Cytopenia Hepatosplenomegaly Osteopenia/
osteoporosis
Cytoreductive
treatment
1 BRDU proliferation assay 3/31/10 56 M Smoldering 341 Yes 50 Yes + + KIT D816V No Yes Yes
2 Clotted 7/28/10 40 M Indolent 20 Yes 10 Yes + + KIT D816V No No No
3 Clotted 6/9/11 65 M Indolent 74 Yes 5 Yes + + KIT D816V Thrombocytopenia No No
4 Clotted 5/12/11 51 F Indolent 188 Yes 30 Yes + + KIT D816V No No Osteoporosis Colon CA s/p R
hemicolectomy
with adjuvant
chemotherapy
5 Did not grow 9/8/10 49 F Indolent 35 Yes 5 Yes + + KIT D816V No Splenomegaly Yes
6 Did not grow 11/3/10 44 M Indolent 105 Yes 30 Yes + + KIT D816V No No Osteoporosis
7 Colonies for morphology 4/14/10 42 F Smoldering 150 Yes 40 Yes + + KIT D816V No Yes No
8 Colonies for morphology 11/15/07 48 F Indolent 287 Yes 40 Yes + + KIT D816V Eosinophilia Splenomegaly /
hepatomegaly
Osteoporosis
9 FACS analysis,
repopulation assay
5/5/10 63 F Indolent 52 Yes 15 Yes + + KIT D816V No Hepatomegaly Yes
10 Repopulation assay 6/9/10 58 F Indolent 29 Yes 10 Yes + + KIT D816V No No Yes
11 Repopulation assay 4/21/10 67 M Indolent 123 Yes 40 Yes + + KIT D816V No No No
12 Frozen, ossicle 7/1/10 37 F Indolent 46 Yes 30 Yes + + KIT D816V No No No
13 Frozen, ossicle 7/7/10 66 F No
mastocytosis
17 No 0 No − − − No No No
14 Frozen, ossicle 8/18/10 51 F Indolent 68 Yes 30 Yes + + KIT D816V No No No
15 Frozen, ossicle 7/14/10 61 F Smoldering 319 Yes 30 Yes + + KIT D816V Thrombocytosis No Yes
16 gene array 1/20/11 MC000299 11FC00007 23 F 2 minor
criteria
10 No b5 Yes − + − No No Osteopenia
17 Gene array 2/17/11 MC000304 11FC00024 41 F Indolent 13 Yes 20 Yes + + − No No No
18 Gene array 3/30/11 MC000328 11FC00048 47 F Indolent 25 Yes 15 Yes + + KIT D816V NO NO NO Imatinib
19 Gene array 3/2/11 MC000306 11FC00031 57 M Indolent 68 Yes 10 Yes + + KIT D816V No No No
20 Gene array 3/31/11 MC000329 11FC00049 40 F Indolent 79 Yes 15 Yes + + KIT D816V No No No
21 Gene array 1/5/11 11FC00001 24 F Indolent 80 Yes 15 Yes + + KIT D816V No No Osteopenia
22 Gene array 1/13/11 11FC00003 27 F Indolent 100 Yes 50 No − − KIT K509I
germline
No No No
23 Gene array 2/9/11 MC000303 11FC00020 55 F Smoldering 119 Yes 30 Yes + + KIT D816V Leukopenia Splenomegaly/
hepatomegaly
No
24 Gene array 3/10/11 MC000318 11FC00038 58 F Aggressive 120 Yes 40 Yes + + KIT D816V/
KRAS G12D
Thrombocytopenia Splenomegaly No
25 Gene array 2/2/11 11FC00015 48 F Smoldering 166 Yes 50 Yes + + KIT D816V No Hepatomegaly No IFN alpha
26 Gene array 3/3/11 MC000307 11FC00032 71 F Indolent 173 Yes 30 Yes + + KIT D816V No No No
27 Normal and abnormal
colonies, adipo and
ostegenic assay
8/26/10 45 F 2 minor
criteria
6 No Scattered
mast cells
Yes − + − No No No
28 Normal and abnormal
colonies, adipo and
ostegenic assay
9/2/10 43 F Indolent 17 Yes 20 Yes − − KIT D816V No No No
29 Normal and abnormal
colonies, adipo and
ostegenic assay
9/9/10 52 M Indolent 24 Yes 15 Yes + + KIT D816V No No Yes
30 Normal and abnormal
colonies, adipo and
ostegenic assay
11/10/10 36 F Indolent 35 Yes 5 Yes + + KIT D816V No No No
31 Normal and abnormal
colonies, adipo and
ostegenic assay
10/27/10 32 F Smoldering 215 Yes 35 Yes + + KIT D816V No No No
32 Normal and abnormal
colonies, adipo and
ostegenic assay
11/18/09 48 M Indolent 65 Yes 5 Yes + + KIT D816V No No Yes
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52 K. Nemeth et al.It is also interesting to consider the possibility that
primarily abnormal BMSCs (due to so far unknown muta-
tions?) might actually facilitate the growth and expansion of
mast cells within the marrow and that the expanded mast
cell population would further impact on the malfunction of
BM stroma. Additional genetic and epigenetic studies are
required to elucidate the pathophysiological mechanisms for
these observations.
We demonstrate that in addition to the growth deficien-
cies, the SM BMSCs have an altered expression of surface
markers. Thus, CD 105 or endoglin is overexpressed in the
abnormal SM BMSCs. The overexpression of endoglin in
mouse fibroblasts resulted in a reduction in extracellular
matrix components (Guerrero-Esteo et al., 1999), and a
decreased cellular migration and altered cellular morphol-
ogy was observed. The expression pattern of CD146 is also of
interest. CD146 (also known as melanoma cell adhesion
molecule) has been reported to be the most specific marker
of skeletal (self renewing) stem cells in the bone marrow
(Bianco et al., 2010; Sacchetti et al., 2007). Thus a lower
expression of this protein suggests that fewer skeletal stem
cells are present in the BM, or may reflect a change in their
functionality, which might explain the skeletal problems
reported in patients with SM. Since the same molecule is
also characteristic of the cell that supplies hematopoietic
support within the BM niche, our finding that CD34+
cells that are co-cultured with the abnormal SM colonies
(i.e., CD146low expression) showed a decrease in engraft-
ment which might also be due to differences in CD146
expression. CD 146 is an adhesion molecule, so the effect on
CD34+ cells might thus relate to a decrease in homing ability
following transplantation. Furthermore, we also observed
significant down-regulation in SM derived BMSCs of CXCL12
(0.5-fold p b 0.0003), PDGFα (0.66-fold p b 0.004), VCAM1
(0.36-fold p b 0.0004) and FGF7 (0.27-fold p b 0.00001) —
all of these factors are known to play a role in supporting
hematopoiesis in the BM niche (Li and Wu, 2011; Nagasawa
et al., 2011; Sugiyama et al., 2006).
Our studies clearly demonstrate that in addition to the
increased number of MCs, the bone marrow stroma is also
involved in the disease and might be responsible for disease
findings. It could be feasible to determine if BMSCs could
serve as a new target for potential therapy in SM, a disease
that at present has no cure.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2015.04.005.
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